Bariatric surgery to treat obesity.

Semin Nephrol

Department of General, Visceral and Vascular Surgery, University Hospital Jena, Germany.

Published: January 2013

Obesity has become a global health problem that contributes to numerous life-threatening and disabling diseases, such as type 2 diabetes mellitus and coronary artery disease. The long-term results of traditional weight loss therapies, including diet, exercise, and medications, are relatively poor. Bariatric surgery is the most effective treatment of morbidly obese patients to allow substantial, sustained weight loss and to improve or resolve obesity-associated comorbidities, thereby reducing mortality. According to US practice guidelines, patients qualify for bariatric surgery with a body mass index of 35 kg/m(2) and associated comorbidities, or a body mass index of 40 kg/m(2), after failure of conservative weight loss measures. Currently, the established procedures in the United States are the laparoscopic Roux-en-Y gastric bypass, adjustable gastric banding, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch. The surgeries vary substantially in their postoperative amount of weight loss, resolution of comorbidities, nutritional requirements, and nature and severity of complications. There is no perfect bariatric surgery, an informed risk and benefit assessment should be made by each patient. The procedures are safe, with a mortality rate of 0.3%. Sustained weight loss depends finally on patient re-education in terms of diet, need for regular exercise, and careful bariatric follow-up evaluation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semnephrol.2012.12.004DOI Listing

Publication Analysis

Top Keywords

weight loss
20
bariatric surgery
16
sustained weight
8
body mass
8
mass kg/m2
8
bariatric
5
weight
5
loss
5
surgery treat
4
treat obesity
4

Similar Publications

Tomato is an important crop worldwide, but groundnut bud necrosis virus (GBNV) often hampers its growth. This study investigates the antiviral potential of bacterial endophytes, including CNEB54, CNEB4, CNEB26, and BAVE5 against GBNV, as well as their ability to enhance immunity and growth in tomato. All four bacterial isolates demonstrated a significant delay in GBNV symptom development 10 days post-inoculation, with disease incidence ranging from 18% to 36% compared to 84% in control.

View Article and Find Full Text PDF

Adults with type 1 diabetes (T1D) are increasingly overweight or obese, in part due to intensive insulin therapy. Newer non-insulin medications targeting both hyperglycemia and weight loss are approved for people with type 2 diabetes. These drugs also reduce cardiovascular disease, the major cause of mortality in people with diabetes.

View Article and Find Full Text PDF

Background And Aims: The laxative lubiprostone has been shown to decrease intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone administered for 48 weeks in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Approach And Results: A randomised placebo-controlled trial was conducted in a specialised MASLD outpatient clinic at the National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.

View Article and Find Full Text PDF

High-Density Lipoprotein Lipid and Protein Cargo and Cholesterol Efflux Capacity Before and After Bariatric Surgery.

Arterioscler Thromb Vasc Biol

January 2025

Department of Medicine, Leon H. Charney Division of Cardiology (S.Z., B.-X.L., A.C., M.F., E.A.F., S.P.H.).

Background: Cholesterol efflux capacity (CEC) of HDL (high-density lipoprotein) is inversely associated with incident cardiovascular events, independent of HDL cholesterol. Obesity is characterized by low HDL cholesterol and impaired HDL function, such as CEC. Bariatric surgery, including Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), broadly leads to improved cardiovascular outcomes, but impacts on risk factors differ by procedure, with greater improvements in weight loss, blood pressure, and glycemic control after RYGB, but greater improvements in HDL cholesterol and CEC levels after SG.

View Article and Find Full Text PDF

Intermittent fasting as a treatment for obesity in young people: a scoping review.

NPJ Metab Health Dis

December 2024

Children's Hospital Los Angeles and Keck School of Medicine of USC, Department of Pediatrics, Center for Endocrinology, Diabetes and Metabolism, Los Angeles, CA USA.

Intermittent fasting focuses on the timing of eating rather than diet quality or energy intake, with evidence supporting its effects on weight loss and improvements in cardiometabolic outcomes in adults with obesity. However, there is limited evidence for its feasibility and efficacy in young people. To address this, a scoping review was conducted to examine intermittent fasting regimens in individuals aged 10 to 25 for the treatment of obesity focusing on methodology, intervention parameters, outcomes, adherence, feasibility, and efficacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!